-+ 0.00%
-+ 0.00%
-+ 0.00%

HUTCHMED Reports Preclinical Antitumor Activity for HMPL-A830

PUBT·11/19/2026 00:00:44
语音播报
HUTCHMED Reports Preclinical Antitumor Activity for HMPL-A830
  • HUTCHMED highlighted HMPL-A830 preclinical results already presented at the EORTC-NCI-AACR cancer therapeutics conference in Barcelona on Nov. 18, 2026.
  • In mouse models, the EGFR-targeted KRAS therapy produced more durable tumor regressions than KRAS G12C inhibitors and outperformed several comparator treatments.
  • An ongoing global Phase Ia trial is evaluating HMPL-A830 in patients with unresectable, advanced or metastatic solid tumors.
  • A September 2026 agreement granted a GSK subsidiary development and commercialization rights outside Mainland China, Hong Kong, Macau and Taiwan.
  • The developer retains responsibility for global Phase I development; the GSK subsidiary will handle subsequent development and commercialization in its licensed territories.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611181900PRIMZONEFULLFEED9880656) on November 19, 2026, and is solely responsible for the information contained therein.